New mRNA Degradation Process Linked to N6-Methyladenosine Modification

A team of researchers from the University of Würzburg in Germany has discovered a novel degradation process for messenger RNA (mRNA) associated with a specific RNA modification called N6-methyladenosine (m6A). This finding improves our understanding of the complex mechanisms regulating protein production in cells and could have significant implications for treating various diseases.

mRNA molecules serve as blueprints for protein production in cells. These blueprints can be modified with chemical changes, such as m6A, which act as additional instructions for the cell. The researchers found that m6A modifications in specific regions of mRNA trigger a rapid and efficient degradation process they named CDS-m6A decay (CMD).

Kathi Zarnack, co-author of the study published in Molecular Cell, explains the importance of this discovery: "m6A is interesting for science because this modification is often altered in people who suffer from metabolic disorders, cancer or heart disease." The newly identified CMD process is particularly crucial for controlling the production of proteins that could be harmful to cells if overproduced.

The study revealed that CMD is most effective when m6A modifications are present in the coding sequence (CDS) of mRNA. This mechanism appears to be especially important for regulating proteins involved in cell differentiation, determining whether a cell becomes a nerve cell, muscle cell, or another type.

According to senior author Julian König, "With our study, we are now contributing to a better understanding and more precise prediction of which mRNAs are particularly sensitive to these drugs" that control m6A addition to mRNA.

The researchers plan to investigate the CMD process further, including how ribosomes recognize the m6A modification and how this targeted mRNA degradation could be applied clinically.